XOMA Royalty Corporation (XOMA)
(Real Time Quote from BATS)
$27.17 USD
+1.01 (3.86%)
Updated Aug 15, 2024 01:40 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XOMA 27.17 +1.01(3.86%)
Will XOMA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XOMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XOMA
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
XOMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?
Other News for XOMA
Buy Rating Affirmed: Xoma’s Strategic Growth and Financial Strength Highlighted
Xoma price target raised by $43 at H.C. Wainwright, here's why
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Genmab (GMAB) and Xoma (XOMA)
XOMA Royalty: Q2 Earnings Snapshot